Area of research
Pulmonary and Respiratory Medicine · Rheumatology
Research interest
Research interests include Chronic Obstructive Pulmonary Disease (COPD) Research, Neuroscience and Neuropharmacology Research, Urticaria and Related Conditions, and Multiple Sclerosis Research Studies.
Dupilumab Efficacy and Safety in Patients with Moderate-to-Severe COPD with Type 2 Inflammation: Pooled Analysis of BOREAS and NOTUS Trials
Dupilumab Improves Health-Related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: Pooled Boreas and Notus Results
Treatment with dupilumab improved quality of life in patients with moderate-to-severe chronic obstructive pulmonary disease and type 2 inflammation: Phase 3 BOREAS trial
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial
S93 Phase 3 NOTUS trial: dupilumab efficacy and safety in patients with moderate-to-severe chronic obstructive pulmonary disease and type 2 inflammation
Dupilumab efficacy and safety in patients with moderate-to-severe COPD with type 2 inflammation: pooled analysis of BOREAS and NOTUS
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Late Breaking Abstract - Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial